Disruption of ETV6 Leads to TWIST1-dependent Progression and Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Prostate Cancer

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2018 Feb 20

PMID 29455655

Citations 14

Authors

Yuan-Chin Tsai

Tao Zeng

Wassim Abou-Kheir

Hsiu-Lien Yeh

Juan Juan Yin

Yi-Chao Lee

Wei-Yu Chen

Yen-Nien Liu

Affiliations

Soon will be listed here.

Abstract

Background: ETS variant gene 6 (ETV6) is a putative tumor suppressor and repressed by epidermal growth factor receptor (EGFR) signaling in prostate cancer. Since EGFR antagonists seem ineffective in castration-resistant prostate cancer (CRPC), we aim to study the role of ETV6 in the development of drug resistance.

Methods: Etv6 target gene was validated by ChIP and promoter reporter assays. Correlation of ETV6 and TWIST1 was analyzed in human clinical datasets and tissue samples. Migration, invasion, and metastasis assays were used to measure the cellular responses after perturbation of ETV6 -TWIST1 axis. Proliferation and tumor growth in xenograft model were performed to evaluate the drug sensitivities of EGFR-tyrosine kinase inhibitors (TKIs).

Results: ETV6 inhibits TWIST1 expression and disruption of ETV6 promotes TWIST1-dependent malignant phenotypes. Importantly, ETV6 is required to the anti-proliferation effects of EGFR-TKIs, partly due to the inhibitory function of ETV6 on TWIST1. We also found that EGFR-RAS signaling is tightly controlled by ETV6, supporting its role in TKI sensitivity.

Conclusions: Our study demonstrates that disruption of ETV6 contributes to EGFR-TKI resistance, which is likely due to derepression of TWIST1 and activation of EGFR-RAS signaling. Our results implicate ETV6 as a potential marker for predicting efficacy of an EGFR-targeted anticancer approach. Combination treatment of TWIST1 inhibitors could sensitize the anti-proliferation effects of EGFR-TKIs.

Citing Articles

Pro-oncogene FBI-1 inhibits the ferroptosis of prostate carcinoma PC-3 cells via the microRNA-324-3p/GPX4 axis.

Liu M, Xu C, Yang H, Jiang Q, Chen G, Wang W J Cancer. 2024; 15(13):4097-4112.

PMID: 38947389 PMC: 11212100. DOI: 10.7150/jca.96306.

Prognostic Values of Gene Copy Number Alterations in Prostate Cancer.

Alfahed A, Ebili H, Almoammar N, Alasiri G, AlKhamees O, Aldali J Genes (Basel). 2023; 14(5).

PMID: 37239316 PMC: 10217731. DOI: 10.3390/genes14050956.

Complex Patterns of Genomic Heterogeneity Identified in 42 Tumor Samples and ctDNA of a Pulmonary Atypical Carcinoid Patient.

Robb T, Tsai P, Fitzgerald S, Shields P, Houseman P, Patel R Cancer Res Commun. 2023; 3(1):31-42.

PMID: 36968225 PMC: 10035512. DOI: 10.1158/2767-9764.CRC-22-0101.

Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer.

Tagliazucchi G, Wiecek A, Withnell E, Secrier M Nat Commun. 2023; 14(1):789.

PMID: 36774358 PMC: 9922305. DOI: 10.1038/s41467-023-36439-7.

MicroRNA-96: A therapeutic and diagnostic tumor marker.

Rahimi H, Mojarrad M, Moghbeli M Iran J Basic Med Sci. 2022; 25(1):3-13.

PMID: 35656454 PMC: 9118275. DOI: 10.22038/IJBMS.2021.59604.13226.

References

Shurtleff S, Buijs A, Behm F, Rubnitz J, Raimondi S, Hancock M . TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995; 9(12):1985-9. View

Liu Y, Yin J, Barrett B, Sheppard-Tillman H, Li D, Casey O . Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis. Mol Cell Biol. 2015; 35(11):1940-51. PMC: 4420926. DOI: 10.1128/MCB.00008-15. View

Puisieux A, Brabletz T, Caramel J . Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014; 16(6):488-94. DOI: 10.1038/ncb2976. View

Chen W, Liu S, Chang Y, Yin J, Yeh H, Mouhieddine T . MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer. Oncotarget. 2014; 6(1):441-57. PMC: 4381606. DOI: 10.18632/oncotarget.2690. View

Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View

Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S . Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood. 2010; 117(5):1673-6. DOI: 10.1182/blood-2009-11-254680. View

Siu M, Tsai Y, Chang Y, Yin J, Suau F, Chen W . Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. Oncogene. 2014; 34(36):4767-76. DOI: 10.1038/onc.2014.414. View

Traish A, Morgentaler A . Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009; 101(12):1949-56. PMC: 2795439. DOI: 10.1038/sj.bjc.6605376. View

Canil C, Moore M, Winquist E, Baetz T, Pollak M, Chi K . Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 2005; 23(3):455-60. DOI: 10.1200/JCO.2005.02.129. View

10.

Gutierrez-Hartmann A, Duval D, Bradford A . ETS transcription factors in endocrine systems. Trends Endocrinol Metab. 2007; 18(4):150-8. DOI: 10.1016/j.tem.2007.03.002. View

11.

Sircar K, Yoshimoto M, Monzon F, Koumakpayi I, Katz R, Khanna A . PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol. 2009; 218(4):505-13. DOI: 10.1002/path.2559. View

12.

Lopez R, Carron C, Oury C, Gardellin P, Bernard O, Ghysdael J . TEL is a sequence-specific transcriptional repressor. J Biol Chem. 1999; 274(42):30132-8. DOI: 10.1074/jbc.274.42.30132. View

13.

Kibel A, Freije D, Isaacs W, Bova G . Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer. 1999; 25(3):270-6. View

14.

Roberts P, Der C . Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26(22):3291-310. DOI: 10.1038/sj.onc.1210422. View

15.

Chang Y, Chen W, Yin J, Sheppard-Tillman H, Huang J, Liu Y . EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1. Cancer Res. 2015; 75(15):3077-86. PMC: 4909124. DOI: 10.1158/0008-5472.CAN-14-3380. View

16.

Martin P, Liu Y, Pierce R, Abou-Kheir W, Casey O, Seng V . Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am J Pathol. 2011; 179(1):422-35. PMC: 3123810. DOI: 10.1016/j.ajpath.2011.03.035. View

17.

Kwok W, Ling M, Lee T, Lau T, Zhou C, Zhang X . Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 2005; 65(12):5153-62. DOI: 10.1158/0008-5472.CAN-04-3785. View

18.

Cai C, Peng Y, Buckley M, Wei J, Chen F, Liebes L . Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene. 2008; 27(22):3201-10. DOI: 10.1038/sj.onc.1210983. View

19.

Haffner M, Aryee M, Toubaji A, Esopi D, Albadine R, Gurel B . Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010; 42(8):668-75. PMC: 3157086. DOI: 10.1038/ng.613. View

20.

Yin J, Pollock C, Tracy K, Chock M, Martin P, Oberst M . Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol. 2007; 27(21):7538-50. PMC: 2169046. DOI: 10.1128/MCB.00955-07. View